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EDITORIAL
Bipolar disorder (BD) is a psychiatric illness typically char-
acterized by recurrent episodes of mania and depression 
associated with a high rate of medical and psychiatric co-
morbidities. Currently approved treatments for BD include 
lithium, valproate, and antipsychotics. However, many 
bipolar patients do not respond adequately to these medica-
tions and continue to have recurrent mood episodes, residual 
symptoms, functional impairment, psychosocial disability, 
DQGVLJQLÀFDQWPHGLFDODQGSV\FKLDWULFFRPRUELGLW\6HYHUDO
studies have reported the reduction in neuronal and glial 
density, mainly in limbic regions, in patients with BD. 
It has been postulated that this disorder might be as-
sociated with temporal progression in phenomenology, 
treatment response, neurobiology, and functional impair-
ment. Therefore, different stages of BD are associated with 
distinct neurobiological mechanisms, such as mitochondrial 
G\VIXQFWLRQR[LGDWLYHVWUHVVLQÁDPPDWLRQDQGQHXURWURSK-
ic dysfunction. These biological markers may be altered in 
distinct stages of BD (early or late). In addition to the bio-
chemical alteration, BD is associated with neuroanatomical 
changes at the onset of this disorder, which are exacerbated 
by the occurrence of further episodes. Accordingly, the 
present issue of the Revista Brasileira de Psiquiatria will 
address mechanisms of neuroprogression in BD. 
Oxidative stress and energetic metabolism appear to be 
closely linked in BD. The mitochondrial dysfunction in BD 
is associated with mitochondrial DNA deletion/mutation/
polymorphism in the neural tissue of BD patients.1 These 
alterations can be accompanied by changes in the complex 
of the mitochondrial electron transport chain, which can 
lead to an elevated level of reactive oxidative species and 
an imbalance between oxidant and antioxidant mechanisms. 
In contrast, oxidative stress may inhibit mitochondrial 
electron transport chain complexes, leading to a decrease 
in ATP production and cellular dysfunction. Antioxidant 
enzyme changes and oxidative damage to lipid and proteins 
have been widely reported in BD patients, and this may be 
the explanation for the apoptosis-mediated cellular death 
and, consequently, decrease in brain volume observed in BD.3 
The excessive increase in reactive oxygen species, resulting 
in oxidative stress and subsequent oxidative damage to lipids, 
proteins and nucleic acids, can lead to the activation of a 
signaling pathway of cell death. In fact, protein and mRNA 
OHYHOV RI %$; DQG*6.E, molecules known as apoptotic 
factors, were found to be altered in BD.2,3 Moreover, studies 
on BD brains have demonstrated decreased levels of Bcl-2 
and brain-derived neurotrophin factor (BDNF), which are 
anti-apoptotic factors.4
Interestingly, there is evidence showing that oxidative 
stress may be increased under conditions in which BDNF is 
decreased in BD.56WXGLHVVKRZWKDWPRRGVWDELOL]HUVVXFK
as lithium and valproate, increase BDNF levels and protect 
against oxidative damage. BDNF is a neurotrophin that is es-
sential for neuronal survival, synaptic plasticity, and cortical 
development. Thus, the impairment in BDNF levels observed 
in BD patients may contribute to brain atrophy and progres-
sive cognitive changes observed in this disorder. In addition, 
reduced levels of peripheral BDNF are found during mania 
and depression but not in euthymic episodes of BD patients, 
further emphasizing the role of this neurotrophin in neuro-
progression of the illness. 
It is important to emphasize that oxidative stress is 
an important activator of microglia, which generate pro-
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GLDWHLQÁDPPDWRU\SURFHVV,QIDFWLWKDVEHHQSRVWXODWHG 
WKDWLQÁDPPDWLRQLVLQYROYHGLQ%'EHFDXVHHOHYDWHGOHYHOV
of cytokines are associated with both depression and mania. 
These cytokines include interleukin-1E (IL-1E), IL-6, and 
tumor necrosis factor-D (TNFD). It is believed that cytokine 
levels are altered during mania and depression phases as 
well as in the asymptomatic period of the disorder. This link 
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of genetic polymorphisms and gene expression. Moreover, it 
KDVEHHQVXJJHVWHGWKDWLQÁDPPDWLRQPLJKWEHDVVRFLDWHG
ZLWKFRJQLWLYHGHÀFLWVREVHUYHGLQ%'SDWLHQWV1
All the mechanisms mentioned above suggest that toxicity 
accumulates during the course of the illness, which might 
explain the increasing clinical severity with BD progression 
(increasing number of episodes). One caveat to consider 
is that further studies are needed to clarify the neuropro-
gression mechanism in BD patients. A better understanding 
of this process is important to identify biological markers 
that could become potential treatment targets in different 
stages of the disorder. Therefore, this issue of the Revista 
Brasileira de Psiquiatria will contribute to enhance knowledge 
and advance research efforts for an effective therapy for 
early stage BD, reducing the disability associated with disease 
progression. These studies open the door to the development 
of rational strategic interventions for different stages of BD.
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